Sarepta Therapeutics (SRPT) Long-Term Investments (2013 - 2026)

Sarepta Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $81.9 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 46.92% year-over-year to $81.9 million; the TTM figure through Mar 2026 stood at $81.9 million (down 46.92% YoY), while the FY2025 annual figure was $9.5 million, down 92.85% from the prior year.
• Long-Term Investments was $81.9 million for Q1 2026 at Sarepta Therapeutics, up from $9.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $181.8 million in Q3 2024 to a low of $1.0 million in Q3 2025.
• Historically, Long-Term Investments has averaged $47.6 million across 5 years, with a median of $19.0 million in 2022.
• Biggest YoY gain for Long-Term Investments was 1970.14% in 2025; the steepest drop was 99.43% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $31.3 million in 2022, then slumped by 39.02% to $19.1 million in 2023, then soared by 597.19% to $133.2 million in 2024, then plunged by 92.85% to $9.5 million in 2025, then soared by 760.67% to $81.9 million in 2026.
• The last three Long-Term Investments figures came in at $81.9 million (Q1 2026), $9.5 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.